Want to see GB:CNSL full AI Analyst Report?
Top Page
Omega Diagnostics
(LSE:CNSL)
Select Model
Select Model
Rating:43Neutral
Price Target:
1.50 p
▼(-18.92% Downside)
Action:Reiterated
Date:09/10/26
The score is held down primarily by weak and volatile financial performance—especially the sharp 2026 profitability reversal and renewed negative free cash flow—combined with a clearly bearish technical setup (price below all key moving averages and negative momentum). Low leverage provides some balance-sheet stability, but valuation support is limited because the P/E is negative due to losses and no dividend yield is available.
Positive Factors
Very low leverage
Conservative leverage materially reduces financial risk and interest burden, giving Omega greater flexibility to withstand operating volatility. A lightly levered balance sheet can also preserve capacity for working capital, restructuring, or targeted investment while the company works to restore profitability.
Negative Factors
Revenue contraction
The return to revenue contraction after the 2024 rebound suggests that demand and commercial momentum have not yet become consistent. Shrinking sales can reduce operating leverage, make fixed costs harder to absorb, and limit the resources available for product investment and growth.
Read all positive and negative factors
Positive Factors
Negative Factors
Very low leverage
Conservative leverage materially reduces financial risk and interest burden, giving Omega greater flexibility to withstand operating volatility. A lightly levered balance sheet can also preserve capacity for working capital, restructuring, or targeted investment while the company works to restore profitability.
Read all positive factors
Omega Diagnostics (CNSL) vs. iShares MSCI United Kingdom ETF (EWC)
Market Cap
£3.33M
Dividend YieldN/A
Average Volume (3M)268.81K
Price to Earnings (P/E)―
Beta (1Y)0.87
Revenue Growth-16.27%
EPS Growth-471.21%
CountryUK
Employees84
SectorHealthcare
Sector Strength45
IndustryMedical - Instruments & Supplies
Share Statistics
EPS (TTM)-0.02
Shares Outstanding237,950,650
10 Day Avg. Volume600,149
30 Day Avg. Volume268,808
Financial Highlights & Ratios
PEG Ratio<0.01
Price to Book (P/B)0.77
Price to Sales (P/S)0.63
P/FCF Ratio-3.17
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price TargetN/A
Price Target UpsideN/A
Rating ConsensusN/A
Number of Analyst Covering0
EPS Forecast (FY)N/A
Revenue Forecast (FY)N/A
Omega Diagnostics Business Overview & Revenue Model
Company Description
Established in 1987 and headquartered in London, UK, Cambridge Nutritional Sciences plc (formerly Omega Diagnostics Group PLC until its name change in September 2023) is a specialist in the development, manufacturing, and supply of medical diagnos...
How the Company Makes Money
Omega Diagnostics makes money primarily by selling diagnostic products and related components into healthcare, laboratory, and industrial supply chains. Key revenue streams typically include: (1) sales of finished IVD test kits (e.g., rapid tests ...
Omega Diagnostics Financial Statement Overview
Summary
Income Statement
34
Negative
Balance Sheet
72
Positive
Cash Flow
41
Neutral
| Breakdown | Mar 2025 | Mar 2024 | Mar 2023 | Mar 2022 | Mar 2021 |
|---|---|---|---|---|---|
Income Statement | |||||
| Total Revenue | 6.97M | 8.33M | 9.77M | 7.55M | 8.54M |
| Gross Profit | 4.28M | 5.00M | 6.05M | 3.17M | 4.75M |
| EBITDA | -392.00K | 2.20M | -73.00K | -2.65M | -382.00K |
| Net Income | -5.83M | 1.57M | -328.00K | -3.86M | -11.33M |
Balance Sheet | |||||
| Total Assets | 7.45M | 13.80M | 13.89M | 14.40M | 17.84M |
| Cash, Cash Equivalents and Short-Term Investments | 2.64M | 4.87M | 5.44M | 5.12M | 1.60M |
| Total Debt | 125.00K | 349.00K | 148.00K | 74.00K | 370.00K |
| Total Liabilities | 1.77M | 2.39M | 4.21M | 4.45M | 6.02M |
| Stockholders Equity | 5.68M | 11.41M | 9.68M | 9.95M | 11.82M |
Cash Flow | |||||
| Free Cash Flow | -1.39M | -142.00K | 548.00K | -3.31M | -4.71M |
| Operating Cash Flow | -1.13M | 83.00K | 607.00K | -3.15M | -3.23M |
| Investing Cash Flow | -810.00K | 2.12M | -2.51M | 5.18M | -493.00K |
| Financing Cash Flow | -232.00K | -251.00K | -265.00K | 1.49M | -502.00K |
Omega Diagnostics Technical Analysis
Negative
1.85
Price Trends
1.78
Negative
1.85
Negative
1.92
Negative
Market Momentum
-0.08
Positive
7.44
Positive
17.18
Positive
Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For GB:CNSL, the sentiment is Negative. The current price of 1.85 is above the 20-day moving average (MA) of 1.81, above the 50-day MA of 1.78, and below the 200-day MA of 1.92, indicating a bearish trend. The MACD of -0.08 indicates Positive momentum. The RSI at 7.44 is Positive, neither overbought nor oversold. The STOCH value of 17.18 is Positive, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Negative sentiment for GB:CNSL.
Omega Diagnostics Peers Comparison
UnderperformOutperform
Sector (51)
Name | Overall Rating | Market Cap | P/E Ratio | ROE | Dividend Yield | Revenue Growth | EPS Growth |
|---|---|---|---|---|---|---|---|
72 Outperform | £607.01M | 60.71 | 3.87% | 1.67% | 28.96% | 39.58% | |
68 Neutral | £194.70M | 24.12 | 23.64% | 3.57% | 13.71% | 27.65% | |
62 Neutral | £110.15M | 54.26 | 3.01% | 4.36% | 2.73% | -65.94% | |
56 Neutral | £16.42M | -3.83 | -16.18% | ― | 13.04% | 15.88% | |
51 Neutral | $7.86B | -0.30 | -43.30% | 2.27% | 22.53% | -2.21% | |
50 Neutral | £27.80M | -13.10 | -55.91% | ― | 40.37% | -13.70% | |
43 Neutral | £3.33M | -0.57 | -69.62% | ― | -16.27% | -471.21% |
* Healthcare Sector Average
GB:CNSL
Omega Diagnostics
1.40
-1.70
-54.84%
GB:AMS
Advanced Medical Solutions
280.50
77.17
37.95%
GB:EKF
EKF Diagnostics Holdings
25.50
-3.80
-12.97%
GB:IXI
IXICO plc
7.50
-4.50
-37.50%
GB:TSTL
Tristel
397.50
55.98
16.39%
GB:ABDX
Abingdon Health PLC
11.00
5.25
91.30%
Omega Diagnostics Corporate Events
Financial DisclosuresRegulatory Filings and ComplianceShareholder Meetings
Cambridge Nutritional Sciences Publishes Annual Report and Sets September AGM
Neutral
Sep 8, 2026
Cambridge Nutritional Sciences plc has published its Notice of Annual General Meeting and Annual Report and Accounts for the year ended 31 March 2026 on its corporate website. The documents provide shareholders and market participants with updated...
Business Operations and StrategyFinancial Disclosures
Cambridge Nutritional Sciences Cuts Costs and Refocuses Growth Amid Profit Slump
Negative
Sep 8, 2026
Cambridge Nutritional Sciences reported a decline in annual revenues to £7.0 million and a swing to a pre-tax loss of £4.4 million, hurt by delayed customer spending and a £3 million goodwill impairment, even as gross margins improv...
Business Operations and StrategyFinancial Disclosures
Cambridge Nutritional Sciences Delays Full-Year Results, Confirms Guidance
Neutral
Aug 17, 2026
Cambridge Nutritional Sciences plc, a specialist medical diagnostics company listed on AIM, focuses on personalised and functional health and nutrition solutions. The group operates in the nutrition diagnostics segment, where demand is being drive...
Business Operations and StrategyFinancial Disclosures
Cambridge Nutritional Sciences Sets Date for 2026 Results and Investor Presentation
Positive
Aug 3, 2026
Cambridge Nutritional Sciences plc has scheduled the publication of its audited results for the year ended 31 March 2026 for Tuesday, 18 August 2026, signaling an upcoming update on the company’s financial and operational performance. Manage...
Glossary
BuyA stock rated as a "Buy" is expected to perform better than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock is likely to deliver higher returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
HoldA stock rated as a "Hold" is expected to perform in line with the overall market or a specific benchmark. This rating indicates that the stock is neither particularly compelling nor unfavorable for investment. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
SellA stock rated as a "Sell" is expected to perform worse than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock may deliver lower returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
Disclaimer
This AI Analyst Stock Report is automatically generated by our AI systems using advanced algorithms and publicly available financial, technical, and market data. While the information provided aims to be accurate and insightful, it is intended for informational purposes only and should not be considered financial advice. Any content created by an AI (Artificial Intelligence) system may contain inaccuracies and/or contain errors. Investing in stocks carries inherent risks, and past performance is not indicative of future results. This report does not account for your personal financial circumstances, objectives, or risk tolerance. Always conduct your own research or consult with a qualified financial advisor before making investment decisions. The analysis and recommendations provided are based on historical and current data and may not fully reflect future market conditions or unexpected developments. Neither the creators of this report nor its affiliated entities guarantee the accuracy, completeness, or reliability of the information presented. Use this report at your own discretion and risk.